CONNECT WITH US
HealthTech

HealthTech

Could an erectile dysfunction drug offer a new way to treat Alzheimer's?

Medical Xpress logo

Published on

Add as a preferred source on Google
Could an erectile dysfunction drug offer a new way to treat Alzheimer's?

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A drug developed to treat erectile dysfunction might seem an unlikely treatment for Alzheimer's disease. But researchers are increasingly interested in whether medicines such as Viagra could also help protect the brain.

These drugs affect blood flow and other processes that may play a role in brain health. An experimental drug called AR1001 has produced encouraging results in a large international clinical trial.

In one group of people with early Alzheimer's, the drug was reported to slow the worsening of symptoms by 31% over a year, compared with a placebo.

AriBio, a South Korean biotechnology company, announced the results at the 19th Clinical Trials on Alzheimer's Disease conference in Boston, U.S. A full scientific paper, reviewed by other researchers, has not yet been published.

The phase 3 trial—the final phase of testing in humans—involved 1,535 people with early Alzheimer's in 13 countries. Participants took either 30 mg of AR1001 or a placebo every day for a year.

Researchers measured changes in memory, thinking and everyday activities. They looked at two groups: everyone who took part in the trial and a smaller group of 604 people who were not taking other Alzheimer's medicines to ease their symptoms, such as donepezil or memantine.

Only this smaller group saw a 31% reduction in worsening symptoms. Across the whole trial, AR1001 did not produce reliable benefits.

Erectile dysfunction drugs work by blocking an enzyme that normally breaks down a chemical messenger—called cGMP—in the body.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.